DOCUSATE SODIUM
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 422.0 | 3.8 | 0 | 7 | 110.0 | 16 | 0.9 |
- CAS
- 577117
- UNII
- F05Q2T2JA0
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 33 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT01773096 | 2013-05-01 | Methylnaltrexone Use for Opioid-induced Postoperative Constipation | Phase 4 | Recruiting |
| NCT01474499 | 2011-09-01 | A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation | Phase 3 | Completed |
| NCT00571896 | 2008-01-01 | The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery | Phase 2/Phase 3 | Completed |
| NCT01879605 | 2007-12-01 | Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery | Phase 4 | Completed |
| NCT00799201 | 2007-08-01 | Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients | Phase 4 | Terminated |
(Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Intramuscular | Injection | 0.02% |
| Oral | Capsule | 8.2MG |
| Oral | Capsule, Hard Gelatin | 0.64MG |
| Oral | Capsule, Sustained Action | 0.001MG |
| Oral | Granule, For Suspension, Extended Release | |
| Oral | Suspension | 0.12% |
| Oral | Suspension, Sustained Action | 0.08% |
| Oral | Tablet | 11MG |
| Oral | Tablet (immed./comp. Release), Coated | 0.5MG |
| Oral | Tablet, Coated | 0.01MG |
| Oral | Tablet, Film Coated | 0.5MG |
| Oral | Tablet, Sustained Action, Film Coated | 0.03MG |
| Topical | Gel | 0.16% |
| Topical | Shampoo | 2% |